Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for potential violations of federal securities laws following the failure of its Phase 2b study of SPN-820 for treatment-resistant depression.
March 11, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Supernus Pharmaceuticals is under investigation by Levi & Korsinsky for potential securities law violations after its SPN-820 study failed to meet primary endpoints.
The failure of the SPN-820 study is a significant setback for Supernus Pharmaceuticals, likely affecting investor confidence and stock price negatively. The legal investigation adds further pressure, suggesting potential misconduct or misrepresentation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100